|
LaunchPad
Baxter India Introduce Therapy In Haemophilia Treatment
Dr Wing-Yen Wong |
Baxter India Private Limited, a wholly owned subsidiary of
Baxter International Inc, announced the launch of Recombinate in India. Recombinate
is a genetically engineered non plasma-derived recombinant factor (rFVIII) through
increased viral safety and uninterrupted supply. Recombinate is indicated for
the prevention and control of haemorrhagic episodes and for the preoperative
management of people with haemophilia A.
Said Dr Wing-Yen Wong, MD, Therapeutic Area Head for Haematology
Clinical Research and Development and Global Senior Medical Director, Bioscience,
Baxter, "The introduction of innovative factor replacement therapies have
helped to advance haemophilia treatment and raise the standard of care around
the world for haemophiliacs. The launch of Recombinate is yet another step in
the advancement of haemophilia care in India." Added Dr Alok Srivastava,
Head-Department of Haematology, Christian Medical College, Vellore, "Introduction
of newer therapies in haemophilia treatment are welcomed both by the industry
and the medical fraternity which would help in bringing relief to the patients
suffering from this condition."
Available since 1992, used in over 41 different countries,
and with in excess of 12 billion IU dispensed, Recombinate is a known choice
for haemophilia management. As a genetically engineered product, Recombinate
contains only a minimal amount of human blood components. It thus minimises
the risk of transmission of blood-borne pathogens. It is also said to offer
a much more dependable supply than plasma-derived FVIII products, which are
reliant upon donations and prone to shortages.
EH News Bureau
|
